Bacterial Meningitis Treatment Guidelines

Recommended Antibiotic Regimens

The European Society of Clinical Microbiology and Infectious Diseases recommends ceftriaxone or cefotaxime alone as empiric therapy for adults <50 years without risk factors 1, 2
For adults >50 years or those with risk factors for Listeria, the European Society of Clinical Microbiology and Infectious Diseases recommends ceftriaxone or cefotaxime PLUS ampicillin/amoxicillin 4
In regions with high pneumococcal resistance, the European Society of Clinical Microbiology and Infectious Diseases recommends adding vancomycin or rifampicin to the third-generation cephalosporin 1, 3

For Streptococcus pneumoniae, the European Society of Clinical Microbiology and Infectious Diseases recommends ceftriaxone or cefotaxime, with addition of vancomycin or rifampicin if decreased susceptibility is suspected; treatment duration 10-14 days 1, 3
For Neisseria meningitidis, the European Society of Clinical Microbiology and Infectious Diseases recommends ceftriaxone or cefotaxime for 7 days 1
For Staphylococcus aureus, the European Society of Clinical Microbiology and Infectious Diseases recommends flucloxacillin, nafcillin, or oxacillin; for MRSA, use vancomycin; treatment duration at least 14 days 1, 3

The European Society of Clinical Microbiology and Infectious Diseases recommends ceftriaxone dosing: 2g IV q12h initially, may be changed to 4g IV q24h after the first 24 hours 6, 7

The European Society of Clinical Microbiology and Infectious Diseases states that sulbactam adds no significant benefit in bacterial meningitis treatment and is not mentioned in current guidelines 1, 2, 3
Monotherapy with cephalosporins may be inadequate for certain pathogens like Listeria monocytogenes, which requires ampicillin coverage 4
Failure to consider local resistance patterns may lead to treatment failure; always consider regional pneumococcal susceptibility 1, 8
Inappropriate empiric therapy is associated with higher rates of severe sequelae and mortality 8

The European Society of Clinical Microbiology and Infectious Diseases recommends outpatient antibiotic therapy may be considered after clinical improvement and at least 5 days of inpatient treatment 6, 7
For outpatient therapy, the European Society of Clinical Microbiology and Infectious Diseases recommends ceftriaxone 2g IV twice daily or 4g IV once daily (after first 24 hours) 6
For penicillin-resistant pneumococci, the European Society of Clinical Microbiology and Infectious Diseases recommends adding rifampicin 600mg PO twice daily 6